Literature DB >> 34608937

Infliximab for Paradoxical Reactions in Pediatric Central Nervous System Tuberculosis.

Yara-Natalie Abo1, Nigel Curtis1,2,3, Joshua Osowicki1,2,3, Gabrielle Haeusler1,2,4, Rachael Purcell1, Seilesh Kadambari1, Matthias De Wachter5, Koen Vanden Driessche6,7,8, Sven Dekeyzer9, Lee Coleman10, Nigel Crawford11, Steve Graham2,3, Ben Marais12,13, Amanda Gwee1,2,3.   

Abstract

Paradoxical reactions in central nervous system tuberculosis (CNS-TB) are associated with significant morbidity and mortality. We describe 4 HIV-uninfected children treated for CNS-TB with severe paradoxical reactions unresponsive to corticosteroids. All made recovery after treatment with infliximab, highlighting the safety and effectiveness of infliximab for this complication, and need for prospective trials.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  central nervous system tuberculosis; infliximab; paradoxical reaction; tuberculous meningitis

Mesh:

Substances:

Year:  2021        PMID: 34608937     DOI: 10.1093/jpids/piab094

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  2 in total

1.  Treatment Outcomes of Childhood Tuberculous Meningitis in a Real-World Retrospective Cohort, Bandung, Indonesia.

Authors:  Heda M Nataprawira; Fajri Gafar; Nelly A Risan; Diah A Wulandari; Sri Sudarwati; Ben J Marais; Jasper Stevens; Jan-Willem C Alffenaar; Rovina Ruslami
Journal:  Emerg Infect Dis       Date:  2022-03       Impact factor: 6.883

2.  Optimizing Antimicrobial and Host-Directed Therapies to Improve Clinical Outcomes of Childhood Tuberculous Meningitis.

Authors:  Fajri Gafar; Ben J Marais; Heda M Nataprawira; Jan Willem C Alffenaar
Journal:  Clin Infect Dis       Date:  2022-08-25       Impact factor: 20.999

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.